Related Experiment Video
Updated: Dec 17, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC
Christian F Ruiz1, Emily D Montal2, John A Haley3
1Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
Abstract:
Cancer cells require extensive metabolic reprograming in order to provide the bioenergetics and macromolecular precursors needed to sustain a malignant phenotype. Mutant KRAS is a driver oncogene that is well-known for its ability to regulate the ERK and PI3K signaling pathways. However, it is now appreciated that KRAS can promote the tumor growth via upregulation of anabolic metabolism. We recently reported that oncogenic KRAS promotes a gene expression program of de novo lipogenesis in non-small cell lung cancer (NSCLC). To define the mechanism(s) responsible, we focused on the lipogenic transcription factor SREBP1. We observed that KRAS increases SREBP1 expression and genetic knockdown of SREBP1 significantly inhibited the cell proliferation of mutant KRAS-expressing cells. Unexpectedly, lipogenesis was not significantly altered in cells subject to SREBP1 knockdown. Carbon tracing metabolic studies showed a significant decrease in oxidative phosphorylation and RNA-seq data revealed a significant decrease in mitochondrial encoded subunits of the electron transport chain (ETC). Taken together, these data support a novel role, distinct from lipogenesis, of SREBP1 on mitochondrial function in mutant KRAS NSCLC.
Insights
Mutant KRAS in non-small cell lung cancer (NSCLC) upregulates the transcription factor SREBP1. SREBP1 knockdown inhibits cancer cell proliferation and impacts mitochondrial function, independent of lipogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Regulation
Background:
- Cancer cells exhibit metabolic reprogramming to support malignant growth.
- Mutant KRAS is a key oncogene influencing signaling pathways and tumor metabolism.
- Oncogenic KRAS promotes de novo lipogenesis in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To investigate the role of SREBP1 in KRAS-driven NSCLC metabolism.
- To elucidate the mechanism by which KRAS influences SREBP1 expression and function.
- To determine the impact of SREBP1 on cancer cell proliferation and mitochondrial activity.
Main Methods:
- Genetic knockdown of SREBP1 in mutant KRAS-expressing NSCLC cells.
- Carbon tracing studies to analyze metabolic pathways.
- RNA sequencing (RNA-seq) to assess gene expression changes, particularly in mitochondrial components.
Main Results:
- KRAS was found to increase SREBP1 expression.
- SREBP1 knockdown significantly inhibited the proliferation of mutant KRAS NSCLC cells.
- Unexpectedly, lipogenesis was not significantly altered by SREBP1 knockdown.
- Carbon tracing revealed decreased oxidative phosphorylation.
- RNA-seq data indicated reduced expression of mitochondrial electron transport chain (ETC) subunits.
Conclusions:
- SREBP1 plays a crucial role in the proliferation of mutant KRAS NSCLC.
- SREBP1 has a novel function in regulating mitochondrial function in this cancer model.
- This function of SREBP1 is distinct from its known role in lipogenesis.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
PI3K/mTOR/AKT Signaling Pathway
Regulation of Nuclear Protein Sorting
Abnormal Proliferation

